Nuo Therapeutics Financial Results
Nuo Therapeutics reported Q3 2026 financial results with total revenue of $1.9 million, an 80% increase year-over-year. The company highlighted strong growth in hospital-based Aurix sales and noted that final 2027 Medicare reimbursement rulings reinforce its long-term growth outlook.
“As many wound care market participants have commented, the broader wound care space remains unsettled resulting from the dramatic January change to reimbursement economics for skin substitutes/grafts which remained unchanged in the final 2027 rulings mentioned above”
David Jorden, Nuo’s Chief Executive and Financial Officer
“As a business, we are prioritizing both reaching the revenue level required for operational breakeven and assessing opportunities to strengthen our capital structure to support Nuo’s next stage of growth.”
David Jorden, Nuo’s Chief Executive and Financial Officer